ThermoGenesis, Biomet ink fibrin sealant deal
This article was originally published in Clinica
Biomet is to access the $450m fibrin sealant market through a development, licence and supply agreement between its orthobiologics division and ThermoGenesis, the Rancho Cordova, California-based developer of automated blood processing systems.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.